Patient selection for transplantation in the myelodysplastic syndromes.
Allogeneic hematopoietic stem cell transplantation remains the only known curative procedure for the myelodysplastic syndromes (MDS). Because the median age at diagnosis for MDS is in the late seventh decade of life, despite the curative potential, transplantation is not undertaken routinely, and careful consideration must be made regarding the appropriateness of the transplant recipient. This article focuses on appropriate patient selection for transplantation for MDS.
Cutler
Corey
C
Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. corey_cutler@dfci.harvard.edu
D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000601:surgery*; D018579:Patient Selection; D012306:Risk; D012720:Severity of Illness Index; D016019:Survival Analysis; D013997:Time Factors; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome